Screener
Theravance Biopharma TBPH Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 8:00 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-093773
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 11) | ||
| Shareholders’ Equity | ||
| Preferred shares, $0.00001 par value per share: 230 shares authorized, no shares issued or outstanding | — | — |
| Ordinary shares, $0.00001 par value per share: 200,000 shares authorized; 51,891 and 51,069 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 1 | 1 |
| Additional paid-in capital | 1,160,238 | 1,156,288 |
| Accumulated other comprehensive income (loss) | (76) | 61 |
| Accumulated deficit | (870,458) | (859,627) |
| Total shareholders’ equity | 289,705 | 296,723 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's common stock?
- Theravance Biopharma (TBPH) reported common stock of $1K in Q2 2026.
- How has Theravance Biopharma's common stock changed year-over-year?
- Theravance Biopharma's common stock decreased by 0.0% year-over-year, from $1K to $1K.
- What is the long-term trend for Theravance Biopharma's common stock?
- Over 3 years (2020 to 2025), Theravance Biopharma's common stock has grown at a 0.0% compound annual growth rate (CAGR), from $1K to $1K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Theravance Biopharma's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude